Lexeo Therapeutics, Inc. (LXEO)
| Market Cap | 357.58M |
| Revenue (ttm) | 654,000 |
| Net Income (ttm) | -60.63M |
| Shares Out | 26.65M |
| EPS (ttm) | -2.28 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 63,596 |
| Open | 14.07 |
| Previous Close | 14.55 |
| Day's Range | 12.76 - 14.57 |
| 52-Week Range | 9.00 - 17.72 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 20.80 (+54.99%) |
| Earnings Date | Dec 11, 2023 |
About LXEO
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations.... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for LXEO stock is "Strong Buy." The 12-month stock price forecast is $20.8, which is an increase of 54.99% from the latest price.
News
Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic
Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights
Completed enrollment of the LEAD Phase 1/2 clinical trial of LX1001 for the treatment of APOE4-associated Alzheimer's disease Received clearance of LX2006 Clinical Trial Application (CTA) in Canada fo...
Lexeo Therapeutics' stock falls 15% in trading debut after its IPO priced below range
Lexeo Therapeutics Inc.'s stock LXEO, -15.01% tumbled 15% in its trading debut on Friday, after the company's initial public offering priced below the proposed price range. The stock priced at $11, be...
Lexeo Therapeutics IPO Registration Document (S-1)
Lexeo Therapeutics has filed to go public with an IPO on the NASDAQ.